Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The de-listing issue should resolve itself.
Several catalysts that should help FDA approval, Trials starting, Sales, and potential new partnerships.
Crickets here, huh? You guys still optimistic on NDRA? I'm starting to get concerned about the lack of news as well as how many days sub $1 with the potential to get de-listed by the NASDAQ
I have always understood that most companies like this don't get taken out until after CE Mark (which they have) and FDA approval (4th Qtr).
Time will tell.
I’ve been following this for two years and there really hasn’t been much clinical progress, but a WHOLE lot of new stock issued. If this really had the technical value you claim, this would have been taken out by now. Good luck.
TAM up to $21+ Billion in 2020 over $25 by 20’s. Per HC Wainwright presentation. All this potential with a current market cap of $20 Million.
The current MC is very low for the potential.
At these prices and the TAM this could be the easiest 10 bagger ever. Time will tell on that though.
Sure ultra Sound is good enough until something better arrives. Wouldn't it be nice it pts. only needed one scan (TAEUS) and didn't need a next step to get diagnosed. (the majority at least)
I am sure he did his DD. Reading the white papers. website, etc
How does your doc know Endra has a great tool if he knows nothing about it? Very little clinical results made public. Almost seems like it is still in beta..
No, wife isn’t sick. No further testing required. I think you are missing the point of discussion. The point is Standard ultrasound can be used to prescreen individuals for fatty liver. The results of the scan determine the next step, if any.
Maybe his the reason they didnt dilute even more you'r right no clue why his on the board
No saying your wify is sick .
That's exactly one of the bigger issues with liver fat if not using a specialist. Too many false negative and false positive. Resulting in people getting pushed through to a specialist and generate huge health care costs without being sick, and of cause the worst, sick people not getting treatment because they didn't use an specialist.
93% of patients referred to a specialist are false negative only about 7% of those declared healthy are in fact sick and progress until they are found.
Second big issue is that people dont get testet period, at least not before they are sick for real.
Ultrasound is great but not for measuring liver fat although SOC until TAEUS arrives.
This video compares most non invasive measurements and is very informative. look @16:30
Maybe but folks on the new drugs that are coming will need to measure the progress as will the Dr's. A radiologist I know who see's more and more Fatty Liver weekly then he was seeing 5-10 years ago thinks this is a great tool.
You sound like me and Zoom I didn't see the need should have invested.
Ultrasound told us it was minimal, so a regular ultrasound machine can determine if one’s fatty liver needs further tests.
They can't quantify mildly fatty can they?
Check out the new presentation especially at the end where it compares the various options.
https://s3.amazonaws.com/cdn.irdirect.net/PIR/957/4797/ENDRA%20Life%20Sciences%20Investor%20Presentation%20Sept%202020%20Final%20V2.pdf
Is her liver over 5 or 25%? If it was my liver I would want to know?
Endra TAEUS can tell you normal Ultrasound cannot.
Not sure, I know. He has a good relationship with one of the other board members who is also a large shareholder.
Why is Lou B on the Board? That makes no sense. What value does someone like him add?? First Clearsign, then leaves. Now Endra.
“
Endra looks very promising, but they need to publish more data and should test in combination with standard non invasive markers, such as blood tests, BMI ect ect, as these are done anyway at the PCP.
All adds up to a better Sensitivity / specificity.”
This is key and Endra doesn’t want to share comparative results.
As I’ve mentioned my wife had an ultrasound on her liver and the medical report indicated a mildly fatty liver with no further tests required.
What additional specificity is provided by Endra’s device?
Great info and read on it, thank you!
I always value your opinion, so much appreciated!!
I think very few knows about Endra.
The point many misses is that gold standard is achieved by a very expensive MRI scanning, and is really not part of standard of care in the early lines of NAFLD, which is where the big market opportunity is for Endra. To diagnose and start treatment of NAFLD in the early stage.
I think the implementation of TAEUS, based on current data, is to replace biopsy, fribroscan and ultrasound at specialist after their Primary Care Physician has established suspicion of NAFLD.
Fact that current major share holders want to buy more shares is great. They paid about .84. Had it been a public offering they would have had to give 15-20% discount on sp anyway, so we might be better of this way.
Endra looks very promising, but they need to publish more data and should test in combination with standard non invasive markers, such as blood tests, BMI ect ect, as these are done anyway at the PCP.
All adds up to a better Sensitivity / specificity.
I know you didn’t ask me but thought I would add my .02.
I don’t think the Market really knows about TAEUS yet that will come with sales and FDA approvals.
The warrants exercised at .70 but they paid approximately.14 for each warrant for a total cost .84 to the investor.
The insiders exercised their warrants a couple of weeks earlier at full price of .87 plus the .14 they paid. Bullish IMO.
Do you think the market is not impressed with these figures and they're not "gold standard" enough to be a disrupter? Also, thoughts on the recent exercise of warrants generating $5 mill for the company? Said that ENDRA "accepted reduced exercise prices".
Interesting video. TAEUS reached AUROC .91 and 0.88 at MRI-PDFF values of 6% and 15%, respectively. So not quite up to gold standard above 6%. So guess TAEUS can be used in the early stages of the disease only as the gold standard of non invasive markers and just rival other non invasive markers >6% but below gold standard. The number here comes from NDRAs own Clinical Feasibility Study on their website. At least this is how I understand the numbers and the essence the video.
During the COVID-19 pandemic, it is important to increase diagnostics for liver disease because a growing number of studies have found that fatty liver increases the risk for severe COVID-19 symptoms. Healio Gastroenterology spoke with Francois Michelon, CEO of ENDRA Life Sciences,
https://www.healio.com/news/hepatology/20200811/qa-new-tool-may-detect-liver-fat-early-on-to-prevent-nash-nafld
What’s the cost of making that kit?
Not a bid deal just needs to go above a dollar for 10 days.
Spoke with IR won’t be a concern if that doesn’t happen by next year.
Any thoughts on the below disclaimer on my TD Brokerage account? Is this b/c of time they've spent below $1? Anyway for us to confirm if it's that or some other listing requirement?
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
a new white paper providing a comprehensive review of the NAFLD-NASH diagnostic technology landscape.
It is posted on ENDRA's website (https://endrainc.com/research-and-media) and we believe it will be of interest to investors, clinicians and potential strategic partners.
I think everyone realizes the pieces are in place and we are waiting.
Europe progress(made difficult by the virus but still in progress), FDA approval, the first P.O., and operating funds are all things in process we are waiting for to occur. Probably some things we don't know that will be positive surprises.
Funding will not be an issue, see the latest SEC filings.
Insider buying is great.
It's hanging on nicely around $1 and where'd all the chatter go?????
ENDRA Life Sciences Granted Additional European Patent As Commercialization Begins
New grant expands coverage of key U.S. platform patent to Europe
ANN ARBOR, MI / ACCESSWIRE / July 22, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued European Patent 3328285 from the European Patent Office (EPO).
"The granting of our second European patent comes at an opportune time, as we're currently focusing on finalizing our first clinical evaluation reference sites in Europe and initiating sales in this key market, where the TAEUS Fatty Liver Imaging Probe System received CE Mark Approval in the first half of the year," said ENDRA's Chief Executive Officer, Francois Michelon.
Kai Thomenius PhD, a research scientist at the Institute of Medical Engineering & Science at The Massachusetts Institute of Technology (MIT) and co-inventor of the patent, said, "This is a novel approach to correcting fat induced image distortion in ultrasound imaging, leveraging the inherent fat and lean tissue contrast of thermoacoustics."
"While our European patent grants are significant because they apply to our platform capabilities in our first commercial market, it is important to understand these patents are supported and strengthened by the fact they are part of a growing IP portfolio, which currently stands at 72 assets, which cover other critical aspects of our technology," concluded Michelon.
Of course Chinese patents are priced at the same value as toilet paper in today’s market..
No clue but the only thing stopping it at this point is the ask at 1.05 with about 40,000 shares.
Any thoughts as to what's happening today? Taking off and love to see this volume!!!
ENDRA Life Sciences Expands Global Technology Protection With New Chinese Patents
Grants further protect ENDRA's TAEUS® platform capabilities in key international market with over 400 million potential NAFLD patients
ANN ARBOR, MI / ACCESSWIRE / July 13, 2020 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued Chinese Patents ZL 2016 8 00267289 and ZL 2019 3 04324291 from the Chinese Intellectual Property Office.
"The granting of these patents further expands the protection of our platform technology in the key international market of China, where an estimated 29.2% of the population is affected by Non-Alcoholic Fatty Liver Disease, according to a recent study published in Hepatology," said ENDRA's Chief Executive
There was no interpretation by me. It was a posting from Endra’s web site..
I don’t believe your interpretation.
It is information straight from Endra’s web site: “Read the clinical trial posted on their website. Seems to me that they are missing about 20% of patients with liver fat >6%. “
Seems believable if it was posted there don’t you think?
Very. I have done enough DD on my own rather then take a strangers interpretation on the internet (who I know nothing about) in regards to a very technical document.
Revealing that you would comment on my understanding but would not answer my question on your understanding, which was:
dndodd's comment:
"It is my understanding TAEUS is very close to being as good as an MRI in quantifying liver fat"
My comment:
dndodd, Your understanding would be incorrect.
I have spoken to several experts that don’t concur with your interpretation.
"It is my understanding TAEUS is very close to being as good as an MRI in quantifying liver fat"
Your understanding would be incorrect.
Dndodd, these are facts from NDRA's filings. Many of your posts are "hopeful thoughts" and not in the realm of science. Good luck to you with this investment.
What “seems” right to you is obviously not reality.
"Is it just me or anyone else questioning the TAEUS' ability to accurately quantify liver fat. Read the clinical trial posted on their website. Seems to me that they are missing about 20% of patients with liver fat >6%. This explains a lot.....
Thank you derkamp
You do not know if GE sees the value or not, pure supposition on your part.
dndodd, I expect you will know the true value before me. GE doesn’t see the value. This would be a rounding error on their tax return..
Followers
|
51
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1240
|
Created
|
10/24/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |